Global Gene Fusion Testing Market to grow with a CAGR of 10.40%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Gene Fusion Testing Market.
According
to TechSci Research report, “Global Gene Fusion Testing Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Gene Fusion Testing
Market has valued at USD 244.30 million in 2022 and is anticipated to witness a
robust growth in the forecast period with a CAGR of 10.51% and will probably
reach USD 850.20 million by 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
The
adoption of gene fusion testing as a standard of care is indeed a driver for
the Global Gene Fusion Testing Market. Gene fusion testing offers a higher
level of diagnostic accuracy, especially in the field of oncology. By
identifying specific fusion events associated with cancer, healthcare providers
can make more precise diagnoses, reducing the risk of misdiagnosis or
under diagnosis. Gene fusion testing plays a pivotal role in tailoring treatment
decisions to individual patients. When specific fusion events are detected,
clinicians can choose targeted therapies that are more likely to be effective.
This approach maximizes treatment efficacy while minimizing side effects,
leading to better patient outcomes. Medical societies and organizations are
increasingly including gene fusion testing in clinical guidelines and
recommendations for specific diseases, particularly in oncology. This formal
endorsement encourages healthcare providers to adopt these tests as a standard
of care. Gene fusion testing is essential for patient stratification in
clinical trials, ensuring that investigational drugs are tested on individuals
who are most likely to benefit. The successful outcomes of such trials
contribute to the adoption of gene fusion testing in clinical practice.
Browse over XX market data Figures and spread through 110 Pages and an
in-depth TOC on "Gene Fusion Testing Market.”
A
diagnostic technique called gene fusion testing uses molecular analysis to look
for and analyses the genetic anomalies known as gene fusions. When two distinct
genes from different chromosomal sites fuse improperly to generate a hybrid
gene, this process is known as gene fusion. This fusion has the potential to
lead to the manufacture of aberrant proteins or alter gene expression, which
may aid in the emergence of a variety of illnesses, including forms of cancer.
In
February 2023, Arima Genomics, Inc., a business that uses 3D genomics to reveal
actionable insights to empower researchers and clinicians working to improve
human health, and Pierian, a company that is now a part of Velsera and develops
precision engines that enable the democratisation of omic data across clinical
and research applications, today announced co-marketing and licensing agreements
that will improve the ability of clinical labs to detect gene fusions. Arima
Genomics' targeted next-generation sequencing (NGS) testing pipelines will be
integrated by Velsera into the Pierian Clinical Genomics Workspace (CGW), the
premier cloud-based platform that offers clinical labs more streamlined and
precise NGS data analysis, interpretation, and reporting. Combining these two
approaches will make it simpler for clinical laboratories to use
sample-to-answer Arima gene fusion testing, assisting them in detecting gene
fusions and other structural variants.
Standardization
and validation are significant challenges in the Global Gene Fusion Testing
Market. Ensuring the accuracy, reliability, and consistency of gene fusion
testing is crucial for its clinical and research applications. Gene fusion
events can be highly diverse, involving different fusion partners, breakpoints,
and fusion variants. Standardizing tests to detect a wide array of fusion
events can be complex. Multiple technologies are used for gene fusion testing,
including PCR, FISH, NGS, and RT-PCR. Each technology has its own protocols,
chemistries, and limitations, making it challenging to standardize across
platforms. Tissue samples used for gene fusion testing can vary in quality, quantity,
and composition. Standardized protocols should account for these variations to
ensure reliable results. The development of standardized reference materials
that mimic clinical samples with known fusion events is essential for
validation. However, creating such materials can be difficult due to the
diversity of fusion events.
Global Gene Fusion Testing Market segmentation is
based on category, Technology, Indication, End User, and Region.
Based on Technology, Global Gene Fusion Testing
Market is segmented into Next-Generation Sequencing (NGS), Fluorescence In-Situ
Hybridization (FISH), Polymerase Chain Reaction (PCR), Immunohistochemistry
(IHC).
Fluorescence In-Situ Hybridization (FISH) is a molecular biology technique used
to visualize and detect the presence or location of specific DNA sequences or
RNA sequences within cells or tissues. It is a powerful tool in genetics and
cytogenetics research, as well as in clinical diagnostics. In FISH, specific
DNA or RNA sequences are targeted using fluorescently labeled probes. These
probes are short, single-stranded pieces of DNA or RNA that are complementary
to the sequence of interest. Probes are designed to bind only to the target
sequence, ensuring specificity. The key feature of FISH is its use of fluorescent
labels. When the probes have successfully hybridized to the target sequences,
they emit fluorescent signals, which can be visualized using fluorescence
microscopy. Each probe is labeled with a distinct fluorescent dye, allowing for
the detection of multiple sequences simultaneously by using different colors.
Based on Region, North America dominated the Global Gene Fusion Testing
Market. The United States has a well-established regulatory framework
for medical devices and diagnostic tests. The Food and Drug Administration
(FDA) plays a pivotal role in the approval and regulation of gene fusion tests,
and its decisions often influence the global market. The prevalence of cancer
and other genetic diseases in North America drives the demand for advanced diagnostic
tools like gene fusion testing. There's a growing emphasis on early and
accurate diagnosis, which further fuels the market. The region attracts
significant investments in healthcare and biotechnology, which includes funding
for research and development of gene fusion testing technologies. Healthcare
providers in North America tend to be early adopters of new technologies,
including gene fusion testing, when they demonstrate clinical utility and
efficacy. Additionally, patients in the region often have access to a wide
range of diagnostic options and may request advanced testing.
Asia-pacific region to fastest growth in
the Global Gene Fusion Testing Market. The Asia-Pacific region has experienced
a notable increase in the incidence of cancer, mirroring global trends. As gene
fusion testing is particularly relevant in the field of oncology, the growing
burden of cancer in APAC drives the demand for advanced diagnostic tools,
including gene fusion tests. APAC is home to a significant portion of the world's
population, including countries like China and India with billions of people.
This large and diverse population provides a substantial patient pool for gene
fusion testing and clinical trials, making it an attractive market for
healthcare companies. Many countries in the Asia-Pacific region are
experiencing economic growth and increasing healthcare expenditure. As
healthcare systems improve and become more accessible, there is greater
capacity for advanced diagnostic tests like gene fusion testing.
Some
of the major companies operating in the Global
Gene Fusion Testing Market include:
- Amoy Diagnostics Co., Ltd.
- ArcherDX (Integerated DNA Technologies, Inc.)
- Biocartis
- Biocare Medical, LLC
- F. Hoffmann-La Roche Ltd.
- Guardant Health, Inc
- Illumina, Inc.
- Myriad Genetics, Inc.
- Natera,
Inc.
- NeoGenomics,
Inc.
- QIAGEN
N.V.
- Thermo
Fisher Scientific Inc
Download Free Sample Report
Customers can also request
10% free customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Gene Fusion Testing. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people
each year, are expected to contribute to a remarkable growth of the Global Gene
Fusion Testing Market in the forecast period," said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based Global management
consulting firm.
Gene
Fusion Testing Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented by Category (Research, Diagnostic), by Technology
(Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH),
Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC)), by Indication
(Solid Tumors, Hematological Malignancies), by End User (Pharmaceutical and
Biotechnology Companies, Hospitals and Diagnostic Laboratories, Academic and
Research Centers), by region, and Competition evaluated
the future growth potential of Global Gene Fusion Testing Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Gene Fusion Testing Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com